ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
64,291.76
0.46%
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
0.00%
US Dollar vs Yen
153.7655
0.13%
Brent Oil
83.495
0.45%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. ヨーロッパ
  5. EU
  6. Mithra Pharmaceuticals SA (MITRA)

  7. Mithra Pharmaceuticals SA (MITRA) ニュース

MITRA

Mithra Pharmaceuticals (MITRA)

Mithra Pharmaceuticals SA
から:
次の項目別のソート:
 Showing the most relevant articles for your search:EU:MITRA
日付受信時刻ニュースソース見出しコード企業名
2024/05/0400 : 30GlobeNewswire Inc.Mithra enters into exclusive negotiations with Gedeon Richter and secures continued funding in the context of its monetization processEU:MITRAMithra Pharmaceuticals SA
2024/04/2914 : 00GlobeNewswire Inc.Mithra updates on offers received in the context of its monetization process and on its Annual Report 2023EU:MITRAMithra Pharmaceuticals SA
2024/04/2214 : 00GlobeNewswire Inc.Mithra secures court protection measures to advance monetization processEU:MITRAMithra Pharmaceuticals SA
2024/03/0815 : 00GlobeNewswire Inc.Mithra reports full year 2023 financial resultsEU:MITRAMithra Pharmaceuticals SA
2024/03/0515 : 01GlobeNewswire Inc.Mithra announces changes to its executive managementEU:MITRAMithra Pharmaceuticals SA
2024/03/0515 : 00GlobeNewswire Inc.Mithra initiates monetization process, receives bridge loan from existing lendersEU:MITRAMithra Pharmaceuticals SA
2024/02/2919 : 42GlobeNewswire Inc.DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phaseEU:MITRAMithra Pharmaceuticals SA
2024/02/1602 : 23GlobeNewswire Inc.Mithra sells shares in Mayne PharmaEU:MITRAMithra Pharmaceuticals SA
2024/02/0615 : 00GlobeNewswire Inc.Mithra updates on cash positionEU:MITRAMithra Pharmaceuticals SA
2024/02/0615 : 00GlobeNewswire Inc.Mithra updates on cash positionEU:MITRAMithra Pharmaceuticals SA
2023/12/2201 : 45GlobeNewswire Inc.Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in IsraelEU:MITRAMithra Pharmaceuticals SA
2023/12/2201 : 45GlobeNewswire Inc.Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in IsraelEU:MITRAMithra Pharmaceuticals SA
2023/12/2101 : 45GlobeNewswire Inc.Mithra Completes Pediatric Study of ESTELLE® in Adolescent PatientsEU:MITRAMithra Pharmaceuticals SA
2023/12/2101 : 45GlobeNewswire Inc.Mithra Completes Pediatric Study of ESTELLE® in Adolescent PatientsEU:MITRAMithra Pharmaceuticals SA
2023/12/1815 : 00GlobeNewswire Inc.Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 TrialEU:MITRAMithra Pharmaceuticals SA
2023/12/1815 : 00GlobeNewswire Inc.Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 TrialEU:MITRAMithra Pharmaceuticals SA
2023/12/0415 : 00GlobeNewswire Inc.Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in ChinaEU:MITRAMithra Pharmaceuticals SA
2023/11/3015 : 00GlobeNewswire Inc.Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United StatesEU:MITRAMithra Pharmaceuticals SA
2023/11/2901 : 45GlobeNewswire Inc.Mithra to hold five presentations on key role of estrogens in women’s health, including Estetrol (E4), at the ESG Congress in AmsterdamEU:MITRAMithra Pharmaceuticals SA
2023/11/0715 : 00GlobeNewswire Inc.Mithra’s NEXTSTELLIS® granted additional patent in the United StatesEU:MITRAMithra Pharmaceuticals SA
2023/11/0715 : 00GlobeNewswire Inc.Mithra’s NEXTSTELLIS® granted additional patent in the United StatesEU:MITRAMithra Pharmaceuticals SA
2023/11/0702 : 52GlobeNewswire Inc.Mithra releases invitation to its extraordinary securities holders’ meetingEU:MITRAMithra Pharmaceuticals SA
2023/10/2614 : 00GlobeNewswire Inc.Mithra and Searchlight Pharma sign DONESTA® licensing agreement for CanadaEU:MITRAMithra Pharmaceuticals SA
2023/10/2314 : 00GlobeNewswire Inc.Mithra to receive EUR 2.5 million milestone payment from Fuji Pharma under ESTELLE® licensing agreementEU:MITRAMithra Pharmaceuticals SA
2023/10/2314 : 00GlobeNewswire Inc.Mithra to receive EUR 2.5 million milestone payment from Fuji Pharma under ESTELLE® licensing agreementEU:MITRAMithra Pharmaceuticals SA
2023/10/1714 : 00GlobeNewswire Inc.Mithra’s Board of Directors to propose the removal of its request for change of the remuneration policy at the Special General MeetingEU:MITRAMithra Pharmaceuticals SA
2023/10/1114 : 15GlobeNewswire Inc.Shareholder LetterEU:MITRAMithra Pharmaceuticals SA
2023/10/1114 : 00GlobeNewswire Inc.Mithra announces update to the agenda of its upcoming special general shareholders’ meetingEU:MITRAMithra Pharmaceuticals SA
2023/10/1101 : 00GlobeNewswire Inc.Mithra to Hold Presentations on Key Role of Estrogens in Women’s Health, Including Estetrol (E4), at FIGO World CongressEU:MITRAMithra Pharmaceuticals SA
2023/10/0514 : 00GlobeNewswire Inc.Mithra Provides an Update in the Context of Recent Market DevelopmentsEU:MITRAMithra Pharmaceuticals SA
 Showing the most relevant articles for your search:EU:MITRA

最近閲覧した銘柄

NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
KO
Coca Cola
PM
XAUUSD
Gold vs US Dollar
CCOM
US30
US 30
NASDAQ
GOOGL
Alphabet
NYSE
CVX
Chevron
NYSE
JPM
JP Morgan Chase
FX
USDJPY
US Dollar vs Yen
CCOM
SILVER
SILVER
USOTC
RHHBY
Roche (QX)
NYSE
MRK
Merck
FX
USDGBP
US Dollar vs Sterling
NYSE
XOM
Exxon Mobil
NASDAQ
AMZN
Amazon.com
COIN
SOLUSD
Solana
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有